Back to Search Start Over

Assessing brain volume changes in older women with breast cancer receiving adjuvant chemotherapy: a brain magnetic resonance imaging pilot study.

Authors :
Chen, Bihong
Chen, Bihong
Sethi, Sean
Jin, Taihao
Patel, Sunita
Ye, Ningrong
Sun, Can-Lan
Rockne, Russell
Haacke, E
Root, James
Saykin, Andrew
Ahles, Tim
Holodny, Andrei
Prakash, Neal
Mortimer, Joanne
Waisman, James
Yuan, Yuan
Somlo, George
Li, Daneng
Yang, Richard
Tan, Heidi
Katheria, Vani
Morrison, Rachel
Hurria, Arti
Chen, Bihong
Chen, Bihong
Sethi, Sean
Jin, Taihao
Patel, Sunita
Ye, Ningrong
Sun, Can-Lan
Rockne, Russell
Haacke, E
Root, James
Saykin, Andrew
Ahles, Tim
Holodny, Andrei
Prakash, Neal
Mortimer, Joanne
Waisman, James
Yuan, Yuan
Somlo, George
Li, Daneng
Yang, Richard
Tan, Heidi
Katheria, Vani
Morrison, Rachel
Hurria, Arti
Source :
Breast Cancer Research; vol 20, iss 1
Publication Year :
2018

Abstract

BACKGROUND: Cognitive decline is among the most feared treatment-related outcomes of older adults with cancer. The majority of older patients with breast cancer self-report cognitive problems during and after chemotherapy. Prior neuroimaging research has been performed mostly in younger patients with cancer. The purpose of this study was to evaluate longitudinal changes in brain volumes and cognition in older women with breast cancer receiving adjuvant chemotherapy. METHODS: Women aged ≥ 60 years with stage I-III breast cancer receiving adjuvant chemotherapy and age-matched and sex-matched healthy controls were enrolled. All participants underwent neuropsychological testing with the US National Institutes of Health (NIH) Toolbox for Cognition and brain magnetic resonance imaging (MRI) prior to chemotherapy, and again around one month after the last infusion of chemotherapy. Brain volumes were measured using Neuroreaderâ„¢ software. Longitudinal changes in brain volumes and neuropsychological scores were analyzed utilizing linear mixed models. RESULTS: A total of 16 patients with breast cancer (mean age 67.0, SD 5.39 years) and 14 age-matched and sex-matched healthy controls (mean age 67.8, SD 5.24 years) were included: 7 patients received docetaxel and cyclophosphamide (TC) and 9 received chemotherapy regimens other than TC (non-TC). There were no significant differences in segmented brain volumes between the healthy control group and the chemotherapy group pre-chemotherapy (p > 0.05). Exploratory hypothesis generating analyses focusing on the effect of the chemotherapy regimen demonstrated that the TC group had greater volume reduction in the temporal lobe (change = - 0.26) compared to the non-TC group (change = 0.04, p for interaction = 0.02) and healthy controls (change = 0.08, p for interaction = 0.004). Similarly, the TC group had a decrease in oral reading recognition scores (change = - 6.94) compared to the non-TC group (change = - 1.21, p for

Details

Database :
OAIster
Journal :
Breast Cancer Research; vol 20, iss 1
Notes :
application/pdf, Breast Cancer Research vol 20, iss 1
Publication Type :
Electronic Resource
Accession number :
edsoai.on1401037504
Document Type :
Electronic Resource